Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Grand View Research | PRODUCT CODE: 1678512

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1678512

GLP-1 Agonists Weight Loss Drugs Market Size, Share & Trends Analysis By Drugs (Semaglutide (Wegovy), Tirzepatide (Zepbound)), By Route of Administration, By Distribution Channel, By Region, And Segment forecasts, 2025 - 2030

PUBLISHED:
PAGES: 153 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

GLP-1 Agonists Weight Loss Drugs Market Growth & Trends:

The global GLP-1 agonists weight loss drugs market size is anticipated to reach USD 48.84 billion by 2030 and is projected to grow at a CAGR of 18.54% from 2025 to 2030, according to a new report by Grand View Research, Inc. The demand for GLP-1 Agonists in weight loss treatments, including Semaglutide (Wegovy), Liraglutide (Saxenda), and Tirzepatide (Zepbound), is fueling significant opportunities in the healthcare sector. These drugs, which have shown effective results in managing obesity and metabolic conditions, are driving market growth. Semaglutide (Wegovy) and Liraglutide (Saxenda) have already established themselves as reliable weight loss therapies, while Tirzepatide (Zepbound) is emerging as a promising option, showing even greater efficacy compared to other drugs in its class. These therapies work by regulating appetite and improving insulin sensitivity, and with growing clinical evidence supporting their use, the acceptance of GLP-1 Agonists in obesity management is increasing.

The introduction of oral versions would not only make these therapies more accessible but also broaden the patient base who prefer non-injection-based therapies. Pharmacies are playing an increasingly important role in the distribution of GLP-1 Agonists. Retail pharmacies, in particular, are gaining traction in fulfilling prescriptions for Wegovy and Saxenda, providing not only access to the medications but also patient education and ongoing support for those managing obesity. Retail pharmacies' ability to offer convenient medication refills and counseling services makes them crucial in supporting the long-term management of weight loss.

While hospital pharmacies are still key players, especially when patients start treatment and require close monitoring, retail pharmacies are taking on a more significant role as patients transition to long-term care. Hospital pharmacies are important during the initial stages of therapy, where medical supervision is critical, but as patients stabilize and progress with treatment, they often shift to retail or specialty pharmacies. These pharmacies play a vital role in providing continued access to therapy and offering specialized services.

Specialty pharmacies and online pharmacies are also becoming more involved in the distribution of GLP-1 Agonists weight loss drugs. These pharmacies can offer tailored services, such as home delivery and personalized medication counseling, which can be particularly beneficial for patients on long-term treatment regimens. By expanding their role, they provide added convenience and support for patients needing consistent access to weight loss therapies.

The growing focus on combating obesity, one of the leading public health challenges, is driving the expansion of the GLP-1 agonists weight loss drug industry. With increasing recognition of the long-term health risks associated with obesity, such as type 2 diabetes, cardiovascular disease, and sleep apnea, there is a rising demand for effective treatments. Tirzepatide's novel mechanism of action, which targets both GLP-1 and GIP receptors, is attracting considerable attention for its superior efficacy and could further boost demand for GLP-1 Agonists.

As the demand for these medications rises, challenges will emerge, particularly in the areas of drug distribution and supply chain management. Ensuring that injectable therapies are consistently available will require robust cold chain logistics and increased focus on patient education to optimize the use of the drugs. Moreover, the development of oral formulations represents a significant opportunity to improve accessibility and adherence, providing a new avenue for pharmaceutical companies to cater to a broader patient population.

GLP-1 Agonists Weight Loss Drugs Market Report Highlights:

  • Based on drug, the semaglutide (wegovy) segment led the market with the largest revenue share of 60.70% in 2024, solidifying its position as the preferred treatment option for obesity management. Semaglutide's proven efficacy in significantly reducing body weight and improving metabolic health, and its growing clinical acceptance make it the leading therapy in this class.
  • Based on route of administration, the parenteral segment led the market with the largest revenue share of 92.7% in 2024. These injectable therapies, administered either weekly or bi-weekly, are preferred due to their proven effectiveness in promoting long-term weight loss and addressing underlying metabolic conditions like insulin resistance.
  • Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 55.46% in 2024. The growing convenience and accessibility offered by retail pharmacies made them the primary point of access for patients using weight loss medications.
  • North America accounted for the largest market share in 2024, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.
Show more
Product Code: GVR-4-68040-512-4

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. GLP-1 Agonists Weight Loss Drugs Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Rising prevalence of obesity
      • 3.3.1.2. Increasing adoption of weight loss drug therapy
      • 3.3.1.3. Rising geriatric population
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. High cost of treatment
      • 3.3.2.2. Stringent regulations pertaining to production and approvals
  • 3.4. GLP-1 Agonists Weight Loss Drugs Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social Landscape
      • 3.4.2.3. Technological Landscape
      • 3.4.2.4. Environmental Landscape
      • 3.4.2.5. Legal Landscape

Chapter 4. GLP-1 Agonists Weight Loss Drugs Market: By Drug Estimates & Trend Analysis

  • 4.1. GLP-1 Agonists Weight Loss Drugs Market: Drug Segment Dashboard
  • 4.2. GLP-1 Agonists Weight Loss Drugs Market: By Drug Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Semaglutide (Wegovy)
    • 4.3.1. Semaglutide (Wegovy) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Liraglutide (Saxenda)
    • 4.4.1. Liraglutide (Saxenda) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Tirzepatide (Zepbound)
    • 4.5.1. Tirzepatide (Zepbound) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Other Drugs
    • 4.6.1. Other Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Estimates & Trend Analysis

  • 5.1. GLP-1 Agonists Weight Loss Drugs Market: Route of Administration Segment Dashboard
  • 5.2. GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Parenteral
    • 5.3.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Segment Dashboard
  • 6.2. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Other Pharmacies
    • 6.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. GLP-1 Agonists Weight Loss Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. GLP-1 Agonists Weight Loss Drugs Market Share, By Region, 2024 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018- 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Norway GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Sweden
      • 7.3.9.1. Sweden GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. Kuwait
      • 7.6.4.1. Kuwait GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. South Africa GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis, 2024
  • 8.5. Company Profiles
    • 8.5.1. Eli Lilly and Company.
      • 8.5.1.1. Participant's Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Recent Developments/ Strategic Initiatives
    • 8.5.2. Pfizer Inc.
      • 8.5.2.1. Participant's Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Recent Developments/ Strategic Initiatives
    • 8.5.3. Novo Nordisk A/S
      • 8.5.3.1. Participant's Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Recent Developments/ Strategic Initiatives
    • 8.5.4. Viking Therapeutics
      • 8.5.4.1. Participant's Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Recent Developments/ Strategic Initiatives
    • 8.5.5. Structure Therapeutics
      • 8.5.5.1. Participant's Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Recent Developments/ Strategic Initiatives
Show more
Product Code: GVR-4-68040-512-4

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 4 Global GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 5 Global GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 North America GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 8 North America GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 9 North America GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 11 U.S. GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 12 U.S. GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 14 Canada GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 Canada GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 17 Mexico GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Europe GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 21 Europe GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Europe GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Germany GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 24 Germany GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 Germany GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 UK GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 27 UK GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28 UK GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 France GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 30 France GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 France GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Italy GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 33 Italy GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 Italy GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Spain GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 36 Spain GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 37 Spain GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Denmark GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 39 Denmark GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Denmark GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 42 Sweden GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Sweden GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Norway GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 45 Norway GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Norway GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 China GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 52 China GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 53 China GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 Japan GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 55 Japan GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 56 Japan GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 India GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 58 India GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 59 India GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Korea GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 61 South Korea GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 South Korea GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Australia GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 64 Australia GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 65 Australia GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Thailand GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 67 Thailand GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Thailand GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 71 Latin America GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 72 Latin America GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 74 Brazil GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 Brazil GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 77 Argentina GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 Argentina GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 South Africa GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 84 South Africa GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 85 South Africa GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 UAE GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 90 UAE GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 91 UAE GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Kuwait GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 93 Kuwait GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 94 Kuwait GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & forecasting
  • Fig. 6 Market formulation & Validation
  • Fig. 7 GLP-1 Agonists Weight Loss Drugs, Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five forces Analysis
  • Fig. 14 Global GLP-1 Agonists Weight Loss Drugs Market: By Drug Movement Analysis
  • Fig. 15 Global GLP-1 Agonists Weight Loss Drugs Market, for Semaglutide (Wegovy), 2018 - 2030 (USD Million)
  • Fig. 16 Global GLP-1 Agonists Weight Loss Drugs Market, for Liraglutide (Saxenda), 2018 - 2030 (USD Million)
  • Fig. 17 Global GLP-1 Agonists Weight Loss Drugs Market, for Tirzepatide (Zepbound), 2018 - 2030 (USD Million)
  • Fig. 18 Global GLP-1 Agonists Weight Loss Drugs Market, for Other Drugs, 2018 - 2030 (USD Million)
  • Fig. 19 Global GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Movement Analys
  • Fig. 20 Global GLP-1 Agonists Weight Loss Drugs Market, for Parenteral 2018 - 2030 (USD Million)
  • Fig. 21 Global GLP-1 Agonists Weight Loss Drugs Market, for Oral, 2018 - 2030 (USD Million)
  • Fig. 22 Global GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Movement Analysis
  • Fig. 23 Global GLP-1 Agonists Weight Loss Drugs Market, for Hospital Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 24 Global GLP-1 Agonists Weight Loss Drugs Market, for Retail Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 25 Global GLP-1 Agonists Weight Loss Drugs Market, for Other Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 26 Regional Marketplace: Key Takeaways GLP-1 Agonists Weight Loss Drugs Market, Region 2018 -
  • Fig. 27 Regional Outlook, 2022 & 2030 GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 28 Global GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 29 North America GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 30 US GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 35 UK GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 36 France GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 38 Spain GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 Japan GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 44 China GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 India GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 46 Australia GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 South Korea GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 Middle East and Africa GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 55 UAE GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 57 Company/Competition Categorization
  • Fig. 58 Company Market Share Analysis, 2024
  • Fig. 59 Company Market Position Analysis, 2024
  • Fig. 60 Strategy Mapping
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!